K Number
K180287
Device Name
GSI Corti
Date Cleared
2018-05-11

(99 days)

Product Code
Regulation Number
874.1050
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The GSI Corti series is indicated for testing of cochlear function in infants, children and adults by measuring otoacoustic emissions (OAEs). The OAEs are generated by a series of clicks that are directed into the ear canal. Otoacoustic emissions are low level audio-frequency sounds that are produced by the cochlea as part of the normal-hearing process. Available evidence suggests that otoacoustic emissions are generated by the cochlea's outer hair cells and that the presence of OAEs. is an indication that the outer hair cells are vidence indicates that these emissions normally occur with normal hearing, or at most, mild hearing loss (usually 30-40 dB HL). The majority of hearing-impaired individuals will be identified by a simple OAE test.
Device Description
Corti test system provides rapid measurement and documentation of Distortion Product Otoacoustic Emissions (DPOAEs) or Transient Evoked Otoacoustic Emissions (TEOAEs) at several frequencies. The system consists of the instrument, probe, printer, single-use eartips replaceable probe tubes and other accessories. The Corti instrument contains the hardware and software for generating the test stimuli, measuring and displaying the OAEs, and storing the results until they are printed. The plastic housing contains circuit boards that provide the signal processing and display the test results. The instrument also contains a rechargeable lithium-ion battery to power the device. The instrument uses a liquid-crystal display (LCD) and three light-emitting diodes (LEDs) to provide a visual display of test status to the operator. Four push buttons located on the keypad of the device allow the user to control testing and printing, and to reset test protocols. The Probe houses the speaker and microphone which produce test stimuli and measure the sound pressure level (SPL) present in the sealed ear canal. Interface of the instrument to the ear canal is accomplished through disposable eartips, which fit onto the probe tube. The disposable eartips are color coded to facilitate easy selection by size. Distortion Product Otoacoustic Emissions (DPOAEs) are acoustic signals that can be detected in the ear canal of a person with normal outer hair cell function, subsequent to stimulation of the auditory system with a pair of pure tones at frequencies f1 and f2. The resulting emission of interest is the distortion product tone at the frequency 2f1-f2. The Corti instrument generates a series of test tones, directs them into the ear canal, and then measures the level of the DPOAE tone generated by the cochlea. By using different test frequencies, the Corti device provides an estimate of outer hair cell function over a wide range of frequencies. Transient Evoked Otoacoustic Emissions (TEOAEs) are acoustic signals that can be detected in the ear canal of a person with normal outer hair cell function, subsequent to stimulation of the auditory system with a series of wideband clicks. The Corti instrument generates a series of clicks, directs them into the ear canal, and then analyzes the spectrum of the returning signal, separating the noise and emission. By using band pass filters, the Corti device provides an estimate of outer hair cell function over a wide range of frequencies
More Information

Not Found

No
The description focuses on standard signal processing techniques (generating stimuli, measuring SPL, analyzing spectrum, band pass filters) and does not mention any AI or ML algorithms for data analysis or interpretation. The software is described as having a "moderate" level of concern, which is less common for devices heavily reliant on complex AI/ML.

No
The device is indicated for testing and measuring cochlear function, which falls under diagnostic purposes, not therapeutic treatment.

Yes

This device is designed to measure otoacoustic emissions to assess cochlear function, and the "Summary of Performance Studies" explicitly mentions "diagnostic performance of the device" and "delay the proper diagnostic of the hearing problem." The "Intended Use" also states, "The majority of hearing-impaired individuals will be identified by a simple OAE test."

No

The device description explicitly states that the system consists of an instrument, probe, printer, and other accessories, and details the hardware components within the instrument and probe (circuit boards, battery, LCD, LEDs, push buttons, speaker, microphone). This indicates it is a hardware device with integrated software, not a software-only medical device.

Based on the provided information, this device is not an In Vitro Diagnostic (IVD).

Here's why:

  • IVDs are used to examine specimens derived from the human body. The GSI Corti series tests cochlear function by measuring otoacoustic emissions directly from the ear canal in response to stimuli. It does not analyze biological samples like blood, urine, or tissue.
  • The intended use is to test cochlear function and identify potential hearing loss. This is a physiological measurement, not a diagnostic test performed on a biological specimen.
  • The device description focuses on the hardware and software for generating stimuli and measuring sound pressure levels in the ear canal. This aligns with an in-vivo measurement device, not an in-vitro diagnostic.

Therefore, the GSI Corti series is a medical device used for physiological testing, not an IVD.

N/A

Intended Use / Indications for Use

The GSI Corti series is indicated for testing of cochlear function in infants, children and adults by measuring otoacoustic emissions (OAEs). The OAEs are generated by a series of clicks that are directed into the ear canal. Otoacoustic emissions are low level audio-frequency sounds that are produced by the cochlea as part of the normal-hearing process. Available evidence suggests that otoacoustic emissions are generated by the cochlea's outer hair cells and that the presence of OAEs. is an indication that the outer hair cells are vidence indicates that these emissions normally occur with normal hearing, or at most, mild hearing loss (usually 30-40 dB HL). The majority of hearing-impaired individuals will be identified by a simple OAE test.

Product codes (comma separated list FDA assigned to the subject device)

EWO

Device Description

Corti test system provides rapid measurement and documentation of Distortion Product Otoacoustic Emissions (DPOAEs) or Transient Evoked Otoacoustic Emissions (TEOAEs) at several frequencies.

The system consists of the instrument, probe, printer, single-use eartips replaceable probe tubes and other accessories. The Corti instrument contains the hardware and software for generating the test stimuli, measuring and displaying the OAEs, and storing the results until they are printed. The plastic housing contains circuit boards that provide the signal processing and display the test results. The instrument also contains a rechargeable lithium-ion battery to power the device. The instrument uses a liquid-crystal display (LCD) and three light-emitting diodes (LEDs) to provide a visual display of test status to the operator. Four push buttons located on the keypad of the device allow the user to control testing and printing, and to reset test protocols.

The Probe houses the speaker and microphone which produce test stimuli and measure the sound pressure level (SPL) present in the sealed ear canal. Interface of the instrument to the ear canal is accomplished through disposable eartips, which fit onto the probe tube. The disposable eartips are color coded to facilitate easy selection by size.

Distortion Product Otoacoustic Emissions (DPOAEs) are acoustic signals that can be detected in the ear canal of a person with normal outer hair cell function, subsequent to stimulation of the auditory system with a pair of pure tones at frequencies f1 and f2. The resulting emission of interest is the distortion product tone at the frequency 2f1-f2.

The Corti instrument generates a series of test tones, directs them into the ear canal, and then measures the level of the DPOAE tone generated by the cochlea. By using different test frequencies, the Corti device provides an estimate of outer hair cell function over a wide range of frequencies.

Transient Evoked Otoacoustic Emissions (TEOAEs) are acoustic signals that can be detected in the ear canal of a person with normal outer hair cell function, subsequent to stimulation of the auditory system with a series of wideband clicks.

The Corti instrument generates a series of clicks, directs them into the ear canal, and then analyzes the spectrum of the returning signal, separating the noise and emission. By using band pass filters, the Corti device provides an estimate of outer hair cell function over a wide range of frequencies

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

ear canal

Indicated Patient Age Range

infants, children and adults

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

The clinical validation was performed to determine substantial equivalence in the performance of the brand name GSI Corti to the ERO-SCAN. These instruments were used to perform Distortion-Product Otoacoustic Emissions (DPOAE) and Transient-Evoked Otoacoustic Emissions (TEOAE). The individual test results were evaluated for overall test result and signal-to-noise ratio at each frequency. The entire data set was evaluated for emission level, signal-to-noise ratio, as well as the noise floor. The diagnostic performance of the device was evaluated on a selection of test subjects. A population of approximately 80% normal hearing was targeted for the study population, with the remaining approximately 20% having a range of impairment from complete impairment (cavity) to mild hearing impairment. For each subject, the following tests were performed. These tests were performed in an alternating sequence, as arbitrarily determined by the clinical investigator. Each set of tests were performed in their entirety at each of the scheduled test times, on each of the two days.

DPOAE: 4 Frequency (2.0 kHz to 5.0 kHz(default DP screening protocol)) – 65/55 dB SPL Primaries – 4 Second Averaging Time

DPOAE: 6 Frequency (1.5 kHz to 6 kHz(default DP diagnostic protocol)) – 65/55 dB SPL Primaries – 4 Second Averaging Time

TEOAE: 6 Frequency (700 Hz to 4 kHz (default diagnostic TE protocol)) – 83 dB SPL Click Stimulus – 64 Second Maximum Time

TEOAE: 6 Frequency (1.5 kHz to 4 kHz (default TE screening protocol)) – 83 dB SPL Click Stimulus – 64 Second Maximum Time

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

The results were analyzed to determine if the device provided equivalent diagnostic results on the subject ears as another equivalent device. The results of the validation are considered evidence, when combined with the verification testing, of the ability of the device to meet the requirements associated with the indications for use.

Based on the data and rationales in the clinical validation report it is concluded that for the indication for diagnose and evaluation of hearing;

  • The devices demonstrates conformity with the essential principles
  • Performance and safety claims have been met and documented
  • All risks regarding indications for use and clinical data have been identified, addressed and evaluated
  • . Risks associated with the use of the devices are acceptable and weighted

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

The detailed information about the validation and verification of PASS/REFER for the OAE is provided in the GSI Corti Manual, e.g., PASS/REFER Criteria, Sensitivity and Specificity etc.

Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.

K150491

Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).

Not Found

§ 874.1050 Audiometer.

(a)
Identification. An audiometer or automated audiometer is an electroacoustic device that produces controlled levels of test tones and signals intended for use in conducting diagnostic hearing evaluations and assisting in the diagnosis of possible otologic disorders.(b)
Classification. Class II. Except for the otoacoustic emission device, the device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, if it is in compliance with American National Standard Institute S3.6-1996, “Specification for Audiometers,” and subject to the limitations in § 874.9.

0

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

May 11, 2018

Grason-Stadler, Inc. Amy Yanta Director of Regulatory Affairs 10395 West 70th Street Eden Prairie, MN 55344

Re: K180287

Trade/Device Name: GSI Corti Regulation Number: 21 CFR 874.1050 Regulation Name: Audiometer Regulatory Class: Class II Product Code: EWO Dated: February 1, 2018 Received: February 1, 2018

Dear Amy Yanta:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

1

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely yours,

Srinivas Nandkumar -S

for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

2

Indications for Use

510(k) Number (if known) K180287

Device Name GSI Corti

Indications for Use (Describe)

The GSI Corti series is indicated for testing of cochlear function in infants, children and adults by measuring otoacoustic emissions (OAEs). The OAEs are generated by a series of clicks that are directed into the ear canal. Otoacoustic emissions are low level audio-frequency sounds that are produced by the cochlea as part of the normal-hearing process. Available evidence suggests that otoacoustic emissions are generated by the cochlea's outer hair cells and that the presence of OAEs. is an indication that the outer hair cells are vidence indicates that these emissions normally occur with normal hearing, or at most, mild hearing loss (usually 30-40 dB HL). The majority of hearing-impaired individuals will be identified by a simple OAE test.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020 See PRA Statement below.

3

Image /page/3/Picture/1 description: The image shows the logo for Grason-Stadler. The logo features a stylized sound wave graphic in light blue on the left. To the right of the sound wave is the text "gsi" in bold, black font. Below "gsi" is the text "Grason-Stadler" in a smaller, thinner, black font.

510(k) Summary as required by 21 CFR 807.92.

Administrative Information

  • Submitter: Grason-Stadler Inc. 10395 West 70th Street Eden Prairie, MN 55344 Tel: 952-947-6097 Fax: 952-278-4401
    Contact Person: Amy Yanta Director of Regulatory Affairs 10393 West 70th Street Eden Prairie, MN 55344 952-947-6097 amyy@diagnostic-group.us

Date Summary Prepared: January 29, 2018

Device Identification

Trade Name: GSI Corti Common Name: audiometer, otoacoustic emission device Device Classification Name: Audiometer Device classification: Class II Panel: Ear Nose & Throat Classification Regulation: 874.1050 Product Code: EWO Predicate Device 1: ER36 Series OAE Test System, cleared on 03/26/2015 via K150491

Device Description

Corti test system provides rapid measurement and documentation of Distortion Product Otoacoustic Emissions (DPOAEs) or Transient Evoked Otoacoustic Emissions (TEOAEs) at several frequencies.

The system consists of the instrument, probe, printer, single-use eartips replaceable probe tubes and other accessories. The Corti instrument contains the hardware and software for generating the test stimuli, measuring and displaying the OAEs, and storing the results until they are printed. The plastic housing contains circuit boards that provide the signal processing and display the test results. The instrument also contains a rechargeable lithium-ion battery to power the device. The instrument uses a liquid-crystal display (LCD) and three light-emitting diodes (LEDs) to provide a visual display of test status to the operator. Four push buttons located on the keypad of the device allow the user to control testing and printing, and to reset test protocols.

The Probe houses the speaker and microphone which produce test stimuli and measure the sound pressure level (SPL) present in the sealed ear canal. Interface of the instrument to the ear canal is

4

Image /page/4/Picture/1 description: The image is a logo for Grason-Stadler. The logo features the letters "gsi" in a bold, sans-serif font, with the "g" slightly offset to the left and a blue sound wave graphic next to it. Below the letters "gsi" is the name "Grason-Stadler" in a smaller, sans-serif font.

accomplished through disposable eartips, which fit onto the probe tube. The disposable eartips are color coded to facilitate easy selection by size.

Distortion Product Otoacoustic Emissions (DPOAEs) are acoustic signals that can be detected in the ear canal of a person with normal outer hair cell function, subsequent to stimulation of the auditory system with a pair of pure tones at frequencies f1 and f2. The resulting emission of interest is the distortion product tone at the frequency 2f1-f2.

The Corti instrument generates a series of test tones, directs them into the ear canal, and then measures the level of the DPOAE tone generated by the cochlea. By using different test frequencies, the Corti device provides an estimate of outer hair cell function over a wide range of frequencies.

Transient Evoked Otoacoustic Emissions (TEOAEs) are acoustic signals that can be detected in the ear canal of a person with normal outer hair cell function, subsequent to stimulation of the auditory system with a series of wideband clicks.

The Corti instrument generates a series of clicks, directs them into the ear canal, and then analyzes the spectrum of the returning signal, separating the noise and emission. By using band pass filters, the Corti device provides an estimate of outer hair cell function over a wide range of frequencies

Device Intended Use

The GSI Corti is a test instrument that measures otoacoustic emissions in infants, children, and adults.

The GSI Corti series is indicated for testing of cochlear function in infants, children and adults by measuring otoacoustic emissions (OAEs). The OAEs are generated by a series of clicks that are directed into the ear canal.

Otoacoustic emissions are low level audio-frequency sounds that are produced by the cochlea as part of the normal-hearing process. Available evidence suggests that otoacoustic emissions are generated by the cochlea's outer hair cells and that the presence of OAEs is an indication that the outer hair cells are viable. Clinical evidence indicates that these emissions normally occur with normal hearing, or at most, mild hearing loss (usually 30-40 dB HL). The majority of hearing-impaired individuals will be identified by a simple OAE test.

Technological Characteristics

A comparison between the subject and predicate device shows that the technological characteristics and indications for use are equivalent. The device employs similar technology to accomplish the same tasks as the predicate. A detailed table is provided below.

| Description | ER36 Series OAE Test System
(K150491) | GSI Corti | Equivalency | |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|------------------|
| Type | Audiometer | Audiometer | same | |
| Regulation
Number | 21 CFR 874.1050
(otoacoustic emission device) | 21 CFR 874.1050
(otoacoustic emission device) | same | |
| Classification
Product Code | EWO | EWO | Grason-Stadler | |
| Regulatory Class | Class II | Class II | same | |
| Indications for Use | The ER36 is a test instrument
that measures otoacoustic
emissions in infants, children,
and adults. | The GSI Corti is a test instrument
that measures otoacoustic
emissions in infants, children,
and adults. | same | |
| | The ER36 series is indicated for
testing of cochlear function in
infants, children and adults by
measuring otoacoustic emissions
(OAEs). The OAEs are generated
by a series of clicks that are
directed into the ear canal. | The GSI Corti series is indicated
for testing of cochlear function
in infants, children and adults by
measuring otoacoustic
emissions (OAEs). The OAEs are
generated by a series of clicks
that are directed into the ear
canal. | same | |
| | Otoacoustic emissions are low
level audio frequency sounds
that are produced by the cochlea
as part of the normal-hearing
process. Available evidence
suggests that otoacoustic
emissions are generated by the
cochlea's outer hair cells and that
the presence of OAEs is an
indication that the outer hair
cells are viable. Clinical evidence
indicates that these emissions
normally occur with normal
hearing, or at most, mild hearing
loss (usually 30-40 dB HL). The
majority of hearing-impaired
individuals will be identified by a
simple OAE test. | Otoacoustic emissions are low
level audio frequency sounds
that are produced by the
cochlea as part of the normal-
hearing process. Available
evidence suggests that
otoacoustic emissions are
generated by the cochlea's outer
hair cells and that the presence
of OAEs is an indication that the
outer hair cells are viable.
Clinical evidence indicates that
these emissions normally occur
with normal hearing, or at most,
mild hearing loss (usually 30-40
dB HL). The majority of hearing-
impaired individuals will be
identified by a simple OAE test. | same | |
| | Target
Population | Infants, children, and adults | Infants, children, and adults | same |
| | OAE Specifications | | | |
| | OAE
Measurement
Type | Distortion-Product OAE
Transient-Evoked OAE | Distortion-Product OAE
Transient-Evoked OAE | same |
| | | DPOAE
Frequency
Range | 1.0 kHz to 12kHz | 1.0 kHz to 12kHz |
| | DPOAE Stimulus
Level | 40 to 65 dB SPL | 40 to 65 dB SPL | same |
| | DPOAE
Automatic
Pass/Fail Test | Yes | Yes | same |
| | DPOAE
Calibration | In-Ear self-calibration | In-Ear self-calibration | same |
| | DPOAE f1/f2
Frequency Ratio | 1.22 | 1.22 | same |
| DPOAE Analysis
Bands | 4 to 6 bands available | 4 to 6 bands available | same | |
| TEOAE
Frequency
Range | 500 Hz to 4000 Hz | 500 Hz to 4000 Hz | same | |
| TEOAE Stimulus
Level | Adjustable, 70 to 85 dB SPL | Adjustable, 70 to 85 dB SPL | same | |
| TEOAE
Automatic
Pass/Fail Test | Yes | Yes | same | |
| TEOAE
Calibration | In-Ear self-calibration | In-Ear self-calibration | same | |
| TEOAE Analysis
Bands | 6 | 6 | same | |
| Instrument Characteristics and Specifications | | | | |
| Instrument Type | Handheld | Handheld | same | |
| Hand held
Housing Shape | 2.5in x 6in | 7 in. x 2.75 in x 1.25 in | Larger device
for better
handle by user | |
| Handheld
Housing
Material | PC-ABS | PC+ABS CX7240 | Same (material
name more
specific) | |
| Housing of Ear
Probe | Machined Aluminum | Machined Aluminum | same | |
| User Controls | 4 button directional keyboard | 4 button directional keyboard | same | |
| 4 Button
Navigation
Switch | Surface mount tactile switches | Surface mount tactile switches | same | |
| Cable-Probe
Connector | Proprietary durable polarized
connector | Proprietary durable polarized
connector | same | |
| Test Records
Stored in
Internal
Memory | Up to 250 tests | Up to 250 tests | same | |
| Memory Type | Flash EEPROM | Flash EEPROM | same | |
| Power Supply | Rechargeable Lithium-Ion
Battery. Not accessible by user. | Rechargeable Lithium-Ion
Battery. Not accessible by user. | same | |
| Maximum | 90 dB SPL | 90 dB SPL | same | |
| Test Probe
Types | Cabled probe | Cabled probe | same | |
| User Indicators | Monochrome or Color Character-
based LCD display; 4 LED
indicators | OLED Display | Provides a
sharper image
for user | |
| Connection to
Computer | USB interface | USB A to micro-B interface | Same (More
specific
description of
USB) | |
| Printer | Bluetooth wireless connection to
AC or battery-powered thermal
printer | Bluetooth wireless connection
to AC or battery-powered
thermal printer | same | |
| Test
Performance | AAMIANSIS3.6:2010
Specifications for Audiometers

IEC 60645-1:2012:
Electroacoustics - Audiometric
Equipment - Part 1: Pure-Tone
Audiometers

IEC 60645-3:2007:
Electroacoustics - Audiometric
Equipment - Part 3: Test Signals
of Short Duration, Second Edition

IEC 60645-6:2009:
Electroacoustics - Audiometric
Equipment - Part 6: Instruments
for the Measurement of
Otoacoustic Emissions, First
Edition 2009-04 | AAMIANSIS3.6:2010

IEC 60645-1:2012

IEC 60645-3:2007

IEC 60645-6:2009 | same | |
| Operational and
Safety | AAMIANSI 60601-1:2005(R):
2012: Medical Electrical
Equipment, Part 1:General
Requirements for Safety, Third
Edition

AAM IANSI IEC
62366:2007:(R)2013:Medical
Devices - Application of Usability
Engineering to Medical Devices,
Second Edition 2007-03-01

ISO 14971:2007: Medical Devices,
Application of Risk Management
to Medical Devices, Second
Edition 2007-03-01 | IEC 60601-1:2005+A1:2012(E)

ANSI/AAMI 60601-1:2005/(R)
2012

AAMI/ANSI/IEC 62366:2015

ISO 14971:2007

UL Registered, File E486032 | Same | |

Equivalence Predicate Chart 1:

5

Image /page/5/Picture/1 description: The image shows the logo for Grason-Stadler. The logo features a blue sound wave graphic on the left, followed by the letters "gsi" in bold, black font. Below "gsi" is the text "Grason-Stadler" in a smaller font size.

6

Image /page/6/Picture/1 description: The image shows the logo for Grason-Stadler (GSI). The logo features a stylized sound wave graphic in light blue, followed by the letters "gsi" in bold, black font. Below "gsi" is the text "Grason-Stadler" in a smaller, black font.

7

Image /page/7/Picture/1 description: The image shows the logo for Grason-Stadler. The logo features a stylized sound wave graphic in light blue on the left. To the right of the sound wave is the text "gsi" in bold, black font, with "Grason-Stadler" in a smaller font size underneath.

8

Image /page/8/Picture/1 description: The image shows the logo for Grason-Stadler, a company that specializes in audiology equipment. The logo features the letters "gsi" in a bold, sans-serif font, with the "g" stylized to include sound waves emanating from it. Below the letters is the name "Grason-Stadler" in a smaller font. The logo is simple and modern, and the use of sound waves in the "g" suggests the company's focus on audiology.

UL Registered, File E359876

Summary of Non-Clinical Testing

Design verification and validation were performed according to current standards for OAE to assure the device meets its performance specifications. EMC and Safety was performed in compliance with recognized standards IEC 60601-1 series, Medical Electrical Equipment – General requirements for basic safety and essential performance. The product meets the requirements from the international standard for OAE measurements IEC 60645 series. Software verification testing were conducted and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in medical Devices." The software for this device was considered as a "moderate" level of concern since a failure in the device may result in unacceptable loud stimuli which might affect the hearing of the patient. Additionally, a malfunction in the device may delay the proper diagnostic of the hearing problem in patients. The detailed information about the validation and verification of PASS/REFER for the OAE is provided in the GSI Corti Manual, e.g., PASS/REFER Criteria, Sensitivity and Specificity etc. Based on the fulfillment of the international standards for OAE, we believe the device is safe and effective. The auditory impedance testing characteristics and safety systems were compared and found to be comparable.

Summary of Clinical Testing

The clinical validation was performed to determine substantial equivalence in the performance of the brand name GSI Corti to the ERO-SCAN. These instruments were used to perform Distortion-Product Otoacoustic Emissions (DPOAE) and Transient-Evoked Otoacoustic Emissions (TEOAE). The individual test results were evaluated for overall test result and signal-to-noise ratio at each frequency. The entire data set was evaluated for emission level, signal-to-noise ratio, as well as the noise floor. The diagnostic performance of the device was evaluated on a selection of test subjects. A population of approximately 80% normal hearing was targeted for the study population, with the remaining approximately 20% having a range of impairment from complete impairment (cavity) to mild hearing impairment. For each subject, the following tests were performed. These tests were performed in an alternating sequence, as arbitrarily determined by the clinical investigator. Each set of tests were performed in their entirety at each of the scheduled test times, on each of the two days.

DPOAE: 4 Frequency (2.0 kHz to 5.0 kHz(default DP screening protocol)) – 65/55 dB SPL Primaries – 4 Second Averaging Time

DPOAE: 6 Frequency (1.5 kHz to 6 kHz(default DP diagnostic protocol)) – 65/55 dB SPL Primaries – 4 Second Averaging Time

TEOAE: 6 Frequency (700 Hz to 4 kHz (default diagnostic TE protocol)) – 83 dB SPL Click Stimulus – 64 Second Maximum Time

TEOAE: 6 Frequency (1.5 kHz to 4 kHz (default TE screening protocol)) – 83 dB SPL Click Stimulus – 64 Second Maximum Time

The results were analyzed to determine if the device provided equivalent diagnostic results on the subject ears as another equivalent device. The results of the validation are considered evidence, when

9

510(k) Number: K180287 GSI Corti

Image /page/9/Picture/1 description: The image shows the logo for Grason-Stadler, also known as GSI. The logo features a stylized blue sound wave graphic on the left, followed by the letters "gsi" in bold, black font. Below "gsi" is the text "Grason-Stadler" in a smaller font size.

combined with the verification testing, of the ability of the device to meet the requirements associated with the indications for use.

Based on the data and rationales in the clinical validation report it is concluded that for the indication for diagnose and evaluation of hearing;

  • The devices demonstrates conformity with the essential principles
  • Performance and safety claims have been met and documented
  • All risks regarding indications for use and clinical data have been identified, addressed and evaluated
  • . Risks associated with the use of the devices are acceptable and weighted

Conclusion

We have compared the intended use and performance characteristics with the predicate device. The Corti was tested according to current standards and the differences found between the devices were related to minor differences of functionality, not in relation to safety and efficiency. The differences found between the devices were related to minor differences of functionality such as the Corti has a different splash screen on the device and user has option to recharge the batteries utilizing the device cradle in addition to using the charging cable. The Corti conforms to the current standards. After analyzing bench testing, safety, EMC, and software validation (with risk analysis) testing we conclude that the Corti is found to be substantially equivalent to the predicate device in technological characteristics and indications for use.